Close Asset Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Close Asset Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-15,000	Closed	-$113K	–	149
2019 Q4	$113K	Hold	15,000	–	–	0.01%	97
2019 Q3	$62K	Hold	15,000	–	–	0.01%	113
2019 Q2	$43K	Hold	15,000	–	–	﹤0.01%	126
2019 Q1	$22K	Buy	15,000 +14,838	+9,159%	+$33.6K	﹤0.01%	149
2018 Q4	$7K	Sell	162 -14,838	-99%	-$50.5K	﹤0.01%	167
2018 Q3	$66K	Hold	15,000	–	–	0.01%	122
2018 Q2	$107K	Hold	15,000	–	–	0.01%	105
2018 Q1	$107K	Hold	15,000	–	–	0.01%	108
2017 Q4	$123K	Hold	15,000	–	–	0.01%	99
2017 Q3	$157K	Hold	15,000	–	–	0.02%	92
2017 Q2	$165K	Buy	+15,000	New	+$151K	0.02%	89

Other funds holding AVDL

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Close Asset Management's AVDL Position: Q1 2020 in Review

Close Asset Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2020, closing a stake of 15,000 shares — an estimated $113K sold.

Close Asset Management first reported a position in AVDL in Q2 2017 and held it in 11 quarters. The position peaked at $165K in Q2 2017. 56 funds tracked by Wall St. Rank hold AVDL as of Q1 2020.

Close Asset Management reported no remaining Avadel Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Close Asset Management sold 15,000 Avadel Pharmaceuticals shares in Q1 2020, an estimated $113K.
Close Asset Management first reported a position in Avadel Pharmaceuticals in Q2 2017 and held it in 11 quarters.
Close Asset Management's Avadel Pharmaceuticals position peaked at $165K in Q2 2017.
56 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2020.

Based on Close Asset Management's 13F filing for Q1 2020, filed 5 May 2020.